HK1124775A1 - Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof - Google Patents

Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof

Info

Publication number
HK1124775A1
HK1124775A1 HK09102356.5A HK09102356A HK1124775A1 HK 1124775 A1 HK1124775 A1 HK 1124775A1 HK 09102356 A HK09102356 A HK 09102356A HK 1124775 A1 HK1124775 A1 HK 1124775A1
Authority
HK
Hong Kong
Prior art keywords
reduced cytotoxicity
phospholipid derivatives
alkyl phospholipid
alkyl
derivatives
Prior art date
Application number
HK09102356.5A
Other languages
English (en)
Inventor
Daniel Perrissoud
Mathias Pietras
Jurgen Engel
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05027823A external-priority patent/EP1800684A1/en
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Publication of HK1124775A1 publication Critical patent/HK1124775A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK09102356.5A 2005-12-19 2009-03-12 Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof HK1124775A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75143805P 2005-12-19 2005-12-19
EP05027823A EP1800684A1 (en) 2005-12-20 2005-12-20 Novel alkyl phospholipid derivatives and uses thereof
PCT/EP2006/069873 WO2007071658A2 (en) 2005-12-19 2006-12-19 Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof

Publications (1)

Publication Number Publication Date
HK1124775A1 true HK1124775A1 (en) 2009-07-24

Family

ID=37942171

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09102356.5A HK1124775A1 (en) 2005-12-19 2009-03-12 Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof

Country Status (13)

Country Link
EP (1) EP1962862B1 (xx)
JP (1) JP5232009B2 (xx)
KR (1) KR101378005B1 (xx)
AR (1) AR058397A1 (xx)
AU (1) AU2006328479B2 (xx)
CA (1) CA2632449A1 (xx)
HK (1) HK1124775A1 (xx)
IL (1) IL191695A (xx)
NO (1) NO20082862L (xx)
PL (1) PL1962862T3 (xx)
RU (1) RU2469727C2 (xx)
UY (1) UY30042A1 (xx)
WO (1) WO2007071658A2 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008068037A1 (en) * 2006-12-08 2008-06-12 Jado Technologies Gmbh Cholesterylamines for the treatment and prevention of infectious diseases
DE102007014375A1 (de) 2007-03-26 2008-10-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oleylphosphocholin
AT505515B1 (de) * 2007-08-02 2009-04-15 Orphanidis Pharma Res Verwendung von miltefosin zur herstellung eines medikaments zur behandlung der cryptosporidiose beim menschen
WO2009090063A1 (en) * 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
ES2732941T3 (es) * 2011-03-04 2019-11-26 Oblita Therapeutics Bvba Oleilfosfocolina para el tratamiento de la micosis
CN102584926B (zh) * 2012-01-12 2014-10-15 浙江大学 利用基于胆固醇和磷酸胆碱两亲小分子制备超分子水凝胶的方法
RU2487708C1 (ru) * 2012-03-12 2013-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) Способ лечения парвовирусной инфекции в19 у детей раннего возраста
CA3024129A1 (en) 2016-05-16 2017-11-23 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
CA3076615A1 (en) 2017-09-21 2019-03-28 The Scripps Research Institute Novel therapies for treating and preventing chronic rhinosinusitis
ES2739773B2 (es) * 2018-08-02 2020-11-17 Univ Alicante Compuestos zwitterionicos de acidos 2-fosfocolina carboxilicos y su uso como agentes citotoxicos
CN115003309B (zh) * 2019-12-02 2024-05-24 阿里量子解决方法公司 一种具有结构式i的化合物的晶型

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
CA1338627C (en) 1985-12-04 1996-10-01 Hansjorg Eibl Pharmaceuticals based on phosphoric acid esters for use in tumor therapy, and process for their preparation
EP0284395B1 (en) 1987-03-24 1993-06-23 Nippon Chemiphar Co., Ltd. Novel glycerol derivative and anti-hypertensive agent
DE3942933A1 (de) * 1989-12-23 1991-06-27 Boehringer Mannheim Gmbh Verwendung von alkylphospholipiden als antivirale arzneimittel und neue phospholipid-derivate
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
DE59205998D1 (de) * 1991-07-04 1996-05-23 Asta Medica Ag Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung
DE4132344A1 (de) 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US6254879B1 (en) 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
FR2683915A1 (fr) * 1991-11-18 1993-05-21 Philips Electronique Lab Appareil d'examen de milieux par echographie ultrasonore.
US6172050B1 (en) 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
DE4222910A1 (de) * 1992-07-11 1994-01-13 Asta Medica Ag Neue Phospholipidderivate
DE4233044A1 (de) 1992-10-01 1994-04-07 Asta Medica Ag Phospholipidderivate, die höhere Elemente der V. Hauptgruppe enthalten
US5958906A (en) 1992-10-01 1999-09-28 Asta-Medica Aktiengesellschaft Phospholipid derivatives containing higher elements of the fifth main group
DE19650778C2 (de) 1996-12-06 2001-01-04 Asta Medica Ag Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie
JP3367892B2 (ja) * 1997-05-22 2003-01-20 株式会社ヨシツカ精機 多段粉末成形プレス
DE19835611A1 (de) * 1998-08-06 2000-02-10 Max Planck Gesellschaft Neuartige Phospholipide mit synthetischen, ungesättigten Alkyl- und Acylketten
PT1135193E (pt) * 1998-12-04 2003-01-31 Max Delbrueck Centrum Agentes para o tratamento de tumores a base de lipossomas e compreendendo tamoxifeno
US6521879B1 (en) 2001-04-20 2003-02-18 Rockwell Collins, Inc. Method and system for controlling an LED backlight in flat panel displays wherein illumination monitoring is done outside the viewing area
DE10148067A1 (de) * 2001-09-28 2003-04-17 Max Planck Gesellschaft Hitzesterilisierbare Alkylphosphocholin-Liposome
JP2005515224A (ja) * 2002-01-14 2005-05-26 ダウ グローバル テクノロジーズ インコーポレイティド テンプレート乳剤からの薬剤ナノ粒子
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
CN1646138B (zh) * 2002-03-25 2010-05-26 碧欧塞根公司 对g2a受体特异性的激动剂配体的制药用途
WO2004012744A1 (de) * 2002-07-30 2004-02-12 Zentaris Gmbh Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
BR0315840A (pt) * 2002-10-30 2005-09-27 Makscientific Corp Fosfolipìdeos de anel substituìdo anti-protozoários
WO2006081452A2 (en) * 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
WO2006122716A1 (en) * 2005-05-18 2006-11-23 Heidelberg Pharma Gmbh Use of ether-linked lysophosphatidylcholines and alkylphosphocholines for the treatment of papilloma virus induced warts and sarcoids

Also Published As

Publication number Publication date
AU2006328479B2 (en) 2012-03-08
NO20082862L (no) 2008-08-27
EP1962862B1 (en) 2013-09-04
UY30042A1 (es) 2007-07-31
IL191695A0 (en) 2009-02-11
AU2006328479A1 (en) 2007-06-28
JP2009519999A (ja) 2009-05-21
PL1962862T3 (pl) 2014-01-31
RU2469727C2 (ru) 2012-12-20
EP1962862A2 (en) 2008-09-03
IL191695A (en) 2013-12-31
JP5232009B2 (ja) 2013-07-10
KR101378005B1 (ko) 2014-03-27
WO2007071658A3 (en) 2007-10-04
CA2632449A1 (en) 2007-06-28
KR20080081326A (ko) 2008-09-09
AR058397A1 (es) 2008-01-30
WO2007071658A2 (en) 2007-06-28
RU2008129597A (ru) 2010-01-27

Similar Documents

Publication Publication Date Title
ZA200804574B (en) Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
HK1124775A1 (en) Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
IL185280A0 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
IL194540A0 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
GB0800745D0 (en) Foamable composition for killing arthropods and uses thereof
ZA200809020B (en) Triazolopyrazine derivatives useful as anti-cancer agents
IL198046A (en) Metastatin derivatives and drugs that include them
GB2464645B (en) Quercetin-3'-O-phosphate and its uses
EP1737458A4 (en) R (-) - 11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF
EP2077262A4 (en) IMINOPYRIDINE DERIVATIVES AND THEIR USE
IL186337A0 (en) Stannsoporfin compositions and administration
IL202496A0 (en) Compounds and uses thereof 849
SI1962862T1 (sl) Derivati alkilfosfolipida z zmanjĺ ano citotoksiäśnostjo in njihova uporaba
ZA200808819B (en) Diketo-piperazine and piperidine derivatives as antiviral agents
GB0616182D0 (en) Design 3
EP1865777A4 (en) STANNSOPORFIN COMPOSITIONS AND ADMINISTRATION
EP1898956A4 (en) ANTITUMORAL COMPOSITIONS AND METHOD
IL196823A0 (en) Tetraarylporphine derivatives and uses thereof
GB0618761D0 (en) Derivatives 2
ZA200706741B (en) Tetrahydroindolone and tetrahydroindazolone derivatives
GB0604519D0 (en) Compounds and uses 2
GB0604516D0 (en) Compounds and uses 3
GB0502169D0 (en) Polite pants
GB0606008D0 (en) 3 Way Powering Load
GB0609834D0 (en) Compounds and their uses

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161219